Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;26(10):458–464. doi: 10.1002/clc.4960261006

Asymmetrical dimethylarginine: A novel risk factor for coronary artery disease

Tse‐Min Lu 1, Yu‐An Ding 1,✉, Min‐Ji Charng 1, Shing‐Jong Lin 1
PMCID: PMC6654648  PMID: 14579916

Abstract

Background: Asymmetrical dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and has been associated with systemic atherosclerosis; however, the role of ADMA in patients with coronary artery disease (CAD) has not been investigated.

Hypothesis: The present study was designed to determine whether the plasma ADMA level predicts the presence of CAD independently, and whether the plasma ADMA level correlates with the extent and severity of coronary atherosclerosis.

Methods: In all, 97 consecutive patients with angina and positive exercise stress test were enrolled prospectively for coronary angiography. According to the result of angiography, the subjects were divided into two groups: Group 1 (n = 46): patients with normal coronary artery or mild CAD (< 50% stenosis of major coronary arteries); group 2 (n = 51): patients with significant cad (≥ 50% stenosis of major coronary arteries). plasma levels of adma and l‐arginine were determined by high‐performance liquid chromatography. in addition, we used coronary atherosclerotic score to assess the extent and severity of cad.

Results: The plasma levels of ADMA in Group 2 patients were significantly higher than those in Group 1 patients (0.66 ± 0.17 μM vs. 0.44 ± 0.09 μM, p < 0.001); these were accompanied by significantly lower plasma l‐arginine/adma ratio in patients with significant cad (group 1 vs. 2: 194.0 ± 55.3 vs. 136.7 ± 50.3, p < 0.001). in a multivariate stepwise logistic regression analysis, both plasma adma level and plasma l‐arginine/adma ratio were identified as independent predictors for cad. moreover, there were significant positive and negative correlations between coronary atherosclerotic score and plasma adma level as well as plasma l‐arginine/adma ratio, respectively (plasma adma level: r = 0.518, p < 0.001; l‐arginine/adma ratio: r = 2 0.430, p < 0.001).

Conclusions: Both plasma ADMA level and plasma L‐arginine/ADMA ratio were useful in predicting the presence of significant CAD and correlated significantly with the extent and severity of coronary atherosclerosis. Our findings suggest that plasma ADMA level may be a novel marker of CAD.

Keywords: asymmetrical dimethylarginine, coronary artery disease, nitric oxide

Full Text

The Full Text of this article is available as a PDF (88.1 KB).

References

  • 1. Moncada S, Higgs A: The L‐arginine—nitric oxide pathway. N Engl J Med 1993; 329: 2002–2012 [DOI] [PubMed] [Google Scholar]
  • 2. Kubes P, Suzuki M, Ganger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651–4655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Garg UC, Hassid A: Nitric oxide‐generating vasodilators and 8‐bromocyclic gaunosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774–1777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Radomski MW, Palmer RMJ, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057–1058 [DOI] [PubMed] [Google Scholar]
  • 5. Creager MA, Cooke JP, Mendelsohn ME: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228–234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium‐dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–27 [DOI] [PubMed] [Google Scholar]
  • 7. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish D, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491–497 [DOI] [PubMed] [Google Scholar]
  • 8. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE: Passive smoking and impaired endothelium‐dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334: 150–154 [DOI] [PubMed] [Google Scholar]
  • 9. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A: Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993; 88: 43–54 [DOI] [PubMed] [Google Scholar]
  • 10. Tousoulis D, Tentolouris C, Crake T, Toutouzas P, Davies GJ: Basal and flow‐mediated nitric oxide production by atheromatous coronary arteries. J Am Coll Cardiol 1997; 29: 1256–1262 [DOI] [PubMed] [Google Scholar]
  • 11. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III: Nitric oxide activity in the human coronary circulation: Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95: 1747–1755 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046–1051 [DOI] [PubMed] [Google Scholar]
  • 13. Böger RH, Bode‐Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847 [DOI] [PubMed] [Google Scholar]
  • 14. Böger RH, Bode‐Böger SM, Thiele W, Junker W, Alexander K, Frölich JC: Biochemical evidence of impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068–2074 [DOI] [PubMed] [Google Scholar]
  • 15. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 1999; 99: 1141–1146 [DOI] [PubMed] [Google Scholar]
  • 16. Kakimoto Y, Akazawa S: Isolation and identification of NG, NG‐ and NG, N'G‐dimethyl‐arginine, N‐epsilon‐mono‐, di‐, and trimethyllysine, and glucosylgalactosyl‐ and galactosyl‐delta‐hydroxylysine from human urine. J Biol Chem 1970; 245: 5751–5758 [PubMed] [Google Scholar]
  • 17. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575 [DOI] [PubMed] [Google Scholar]
  • 18. Leiper J, Vallance P: Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542–548 [DOI] [PubMed] [Google Scholar]
  • 19. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242–247 [DOI] [PubMed] [Google Scholar]
  • 20. Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S: Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L‐arginine in regenerated endothelial cells. Br J Pharmacol 1995; 115: 1001–1004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T: Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425–2430 [DOI] [PubMed] [Google Scholar]
  • 22. Surdacki A, Nowichi M, Sandmann J, Tsikas D, Böger RH, Bode‐Böger SM, Kruszelnicka‐Kwiatkowska O, Kokot F, Dubiel JS, Frölich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–658 [DOI] [PubMed] [Google Scholar]
  • 23. Lundman P, Eriksson MJ, Stühlinger M, Cooke JP, Homsten A, Tornvall P: Mild‐to‐moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111–116 [DOI] [PubMed] [Google Scholar]
  • 24. Böger RH, Bode‐Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC: Restoring vascular nitric oxide formation by L‐arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336–1344 [DOI] [PubMed] [Google Scholar]
  • 25. Zoccali C, Bode‐Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatina LS, Cataliotti A, Bellanuova I, Ferno I, Frölich JC, Böger RH: Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end‐stage renal disease: A prospective study. Lancet 2001; 358: 2113–2117 [DOI] [PubMed] [Google Scholar]
  • 26. Valkonen VP, Pälvä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127–2128 [DOI] [PubMed] [Google Scholar]
  • 27. Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernam FJ: Relation of C‐reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000; 86: 205–207 [DOI] [PubMed] [Google Scholar]
  • 28. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrane D, Creager MA, Selwyn AP, Ganz P: Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75 (suppl B): 71–74 [DOI] [PubMed] [Google Scholar]
  • 29. Schächinder V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long‐term outcome of coronary heart disease. Circulation 2000; 101: 1899–1906 [DOI] [PubMed] [Google Scholar]
  • 30. Drexler H, Zeiher AM, Meinzer K, Just H: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients with L‐arginine. Lancet 1991; 338: 1546–1550 [DOI] [PubMed] [Google Scholar]
  • 31. Lerman A, Burnett JC, Higano ST, McKinley LJ, Holmes DR: Long‐term L‐arginine supplementation improves small‐vessel coronary endothelial function in humans. Circulation 1998; 97: 2123–2128 [DOI] [PubMed] [Google Scholar]
  • 32. Böger RH, Bode‐Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287–2295 [DOI] [PubMed] [Google Scholar]
  • 33. Walker HA, McGing E, Fisher I, Böger RH, Bode‐Böger SM, Jackson G, Ritter JM, Chowienczyk PJ: Endothelium‐dependent vasodilation is independent of the plasma L‐arginine/ADMA ratio in men with stable angina. J Am Coll Cardiol 2001; 38: 499–505 [DOI] [PubMed] [Google Scholar]
  • 34. MacAllister RJ, Parry H, Kimoto M: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533–1540 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092–3095 [DOI] [PubMed] [Google Scholar]
  • 36. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA: Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high‐performance liquid chromatography. Anal Biochem 2002; 303: 131–137 [DOI] [PubMed] [Google Scholar]
  • 37. Jin JS, D'Alecy LG: Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996; 28: 439–446 [DOI] [PubMed] [Google Scholar]
  • 38. Bogle RG, MacAllister RJ, Whitley GS, Vallance P: Induction of NG‐monomethyl‐L‐arginine uptake: A mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269: C750–756 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES